Regulation - Research, Financial

Filter

Current filters:

ResearchFinancial

Popular Filters

1 to 25 of 27 results

Curis plunges on negative CUCD-427 news; 3rd-qtr loss down

07-11-2013

Oncology focussed US biotech firm Curis saw its shares sink 21% to $3.08, after it revealed receipt of…

BiotechnologyCUCD-427CurisFinancialNorth AmericaOncologyRegulationResearch

The case for Insmed's CF drug candidate Arikace; analysts' views

05-07-2013

The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

24-05-2013

At a meeting today with industry analysts, senior leaders from the Janssen pharmaceutical companies of…

FinancialJanssenJohnson & JohnsonPharmaceuticalRegulationResearch

Europe falling behind USA and China as attractive for life sciences sector

22-04-2013

Intellectual property specialists Marks & Clerk's latest Life Sciences Report unveils the changing landscape…

BiotechnologyFinancialGlobalPatentsPharmaceuticalRegulationResearch

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone

19-04-2013

Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Sinovac Biotech flu vaccine OKed in Mexico; EV71 results; financials

18-04-2013

In what was a busy news day for Sinovac Biotech (Nasdaq: SVA), a leading provider of vaccines in China,…

BiotechnologyEV71FinancialRegulationResearchSinovac BiotechSouth America

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"

23-11-2012

The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

Extraneous clinical data collection costs drug developers $4-$6 billion a year, says Tufts CSDD

06-11-2012

One out of every five procedures performed during later stage clinical trials collects extraneous data…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulationResearch

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Medicines Australia sets up new taskforce on transparency for payments to doctors

14-08-2012

Medicines Australia has invited the Australian Medical Association, the Royal Australian College of Physicians,…

Asia-PacificFinancialMarkets & MarketingPharmaceuticalRegulationResearch

US health care reform looks to squeeze players up and down the value chain

09-08-2012

This summer's landmark Supreme Court decision to uphold the USA's Patient Privacy and Affordable Care…

BiotechnologyFinancialHealthcareNorth AmericaPharmaceuticalRegulationResearch

More guidelines needed to grow regenerative medicine market, report finds

11-06-2012

Standardized research guidelines are needed to control and encourage the development of gene therapy…

BiotechnologyFinancialGlobalPoliticsRegulationResearch

Optimism and concerns of Netherlands' Biotech industry

17-05-2012

Major trends and developments in the Dutch biotechnology sector, mainly based on the expectations voiced…

BiotechnologyEuropeFinancialRegulationResearch

European governments must ensure R&D is converted into new businesses, new products

27-03-2012

National governments in Europe need to do more to ensure that R&D innovation in the biotech industry…

BiotechnologyEuropeFinancialRegulationResearch

ThromboGenics confident as it plans for ocriplasmin launch

12-03-2012

Belgian biopharma firm ThromboGenics (Euronext Brussels: THR) says that, over the past 12 months, it…

BiotechnologyFinancialocriplasminOphthalmicsRegulationResearchThromboGenics

GTx stock takes a pounding as FDA puts clinical hold on Capesaris trial

24-02-2012

Tennessee, USA-based GTx (Nasdaq: GTXI) saw its shares plunge 30% to $3.98 earlier this week, after…

CapesarisFinancialGTxNorth AmericaOncologyPharmaceuticalRegulationResearch

Threats to US biomedical industry viewed by CEOs

12-01-2012

Access to capital, a burdensome and uncertain regulatory environment and lack of innovation and productivity…

BiotechnologyFinancialNorth AmericaPharmaceuticalRegulationResearch

European Medicines Agency’s 2012 work program and budget

18-12-2011

The European Medicines Agency’s Management Board, at its meeting on 15 December 15, adopted the…

BiotechnologyEuropeFinancialGenericsPharmaceuticalRegulationResearch

Where to now for UK Life Sciences?

16-12-2011

The 2012 UK Life Science Industry Leaders Survey* highlights a concern that the UK is losing its position…

BiotechnologyEuropeFinancialPharmaceuticalPricingRegulationResearch

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing

21-10-2011

US biotech firm ImmunoGen (Nasdaq: IMGN) says that SAR3419 has started Phase II testing, which triggers…

AubagioBiotechnologyFinancialGenzymeImmunoGenNeurologicalOncologyPharmaceuticalRegulationResearchSanofi

1 to 25 of 27 results

Back to top